Navigation Links
Vaccination reduces the risk of unvaccinated badger cubs testing tuberculosis positive
Date:12/12/2012

New evidence from a four-year field study has shown that BCG vaccination reduces the risk of tuberculosis infection in unvaccinated badger cubs in vaccinated groups, as well as in badgers that received the vaccine.

The research, published today in the journal PLOS ONE provides the strongest evidence to date that unvaccinated badger cubs can be indirectly protected from TB infection when some of the badgers in their social group are vaccinated. By studying rates of new cases of TB in cubs in vaccinated social groups, researchers have shown that the risk of non-vaccinated cubs testing positive was reduced by almost 80 per cent when more than a third of badgers in their group had been vaccinated.

The results come from a controlled clinical field trial of badger vaccination, conducted by the Animal Health and Veterinary Laboratories Agency (AHVLA) and the Food and Environment Research Agency (Fera), in an area in Gloucestershire where TB is highly prevalent in the badger population.

Dr Steve Carter of Fera and lead author of the latest research said: "One concern about the effectiveness of badger vaccination is that new-born cubs might acquire TB before they first emerge above ground. As the vaccine is not expected to benefit infected individuals it has been suggested that by the time cubs emerge and are available for vaccination they might have already been exposed to TB. Therefore, vaccination for them may be too late. This study indicates that vaccination of badgers above ground can indirectly protect unvaccinated cubs before they emerge from the sett".

The latest analyses were conducted by a team of scientists at Fera, AHVLA and the Universities of Newcastle and Strathclyde.

Professor Robbie McDonald, an author of the paper and now at the University of Exeter said: "This striking result in cubs shows a protective effect at the social group level and is important evidence that vaccination not only has a direct benefit to vaccinated badgers, but can also reduce the infectivity of TB within a badger social group that has been vaccinated."

But he cautioned: "Although this is an encouraging development, the costs and benefits of vaccinating badgers for controlling disease in cattle are not yet well understood".

"This means that it is a hard choice for farmers to make without further information and trials of how it would work in practice. The current Badger Vaccine Deployment Project in Gloucestershire and experience in the Welsh Government's badger vaccine project will help deliver this experience and knowledge."


'/>"/>

Contact: Louise Vennells
L.Vennells@exeter.ac.uk
44-139-272-2062
University of Exeter
Source:Eurekalert

Related biology technology :

1. Masaryk Memorial Cancer Institute Reduces Losses and Administrative Overhead With Ekahau RTLS
2. R&D/Leverages New Opti-Sim Virtual Prototyping Tool Saves Time and Money for PET Packaging Industry -- and Reduces Waste
3. Computer vision reduces risk in clinical trials
4. Phase II Data Presented at ACNP 2012 Shows Novel Antidepressant GLYX-13 Significantly Reduces Depression Scores Within Hours
5. Members of Congress, Cancer Experts Address Impact of Genetic Testing on Cancer
6. LABS, Inc. Earns AABB Accreditation for Donor Testing
7. Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services
8. India In Vitro Diagnostics Market Outlook to 2017- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture
9. HPV Testing for Cervical Cancer Risk Patients set to Increase
10. Premier Research Expands Salt Lake City and Phoenix Testing Facilities Adding 50% Capacity
11. Arsenic Testing Proves Organic Baby Formula Safe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... WA (PRWEB) , ... March 01, 2017 , ... ... research into the physiology of aging into clinical applications, announces the formation of ... proprietary oral-transmucosal dosage form of resveratrol, the drug which has been discussed in ...
(Date:2/28/2017)... Linda, Ca (PRWEB) , ... February 28, 2017 , ... ... molecular interactions. SPR is an optical phenomenon that is sensitive to changes in the ... resonance condition is affected by changes in refractive index occurring up to 300 nm ...
(Date:2/28/2017)... , Feb. 28, 2017  Phosphorus, a ... today the formation of the Phosphorus Scientific Advisory ... experts chosen to advise the company on the ... multi-site research initiatives. Please visit http://phosphorus.com/about-us/ ... initiatives. "We,ve gathered some of the ...
(Date:2/28/2017)... -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing ... diseases, asthma and allergic diseases and cancer, today ... full year ended December 31, 2016 and provided ... clinical highlights. "During 2016, we made ... starting five clinical trials across our XmAb portfolio.  ...
Breaking Biology Technology:
(Date:2/8/2017)... 7, 2017 The biometrics market has ... confluence of organizations, desires to better authenticate or ... (password and challenge questions), biometrics is quickly working ... The market is driven by use cases, though ... and enterprise uses cases, with consumer-facing use cases ...
(Date:2/7/2017)... New York , February 7, 2017 ... as ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or ... management and electronic transaction processing services, is pleased to ... of the Company. Effective January 31, 2017, ... the Board of Directors, CEO and President.  An experienced ...
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, Inc. ... immuno-oncology company specializing in the development of innovative ... treatment of cancer and metastatic disease, announced today ... GMP manufacturing of a second clinical lot of ... folate receptor alpha. The manufactured vaccine product will ...
Breaking Biology News(10 mins):